Synthesis and evaluation of human phosphodiesterases (PDE) 5 inhibitor analogs as trypanosomal PDE inhibitors. 2. Tadalafil analogs by Ochiana, Stefan O. et al.
Synthesis and evaluation of human phosphodiesterases (PDE) 5 inhibitor analogs as 
trypanosomal PDE inhibitors. 2. Tadalafil analogs 
Stefan O. Ochianaa, Alden Gustafsonb, Nicholas D. Blandb, Cuihua Wanga, Michael J. Russoa, Robert K. 
Campbellb, and Michael P. Pollastria* 
 
aNortheastern University Department of Chemistry and Chemical Biology, 417 Egan Research Center, 360 Huntington Avenue, Boston, MA 02115. 
bMarine Biological Laboratory, Josephine Bay Paul Center for Comparative Molecular Biology and Evolution, 7 MBL Street, Woods Hole, MA 02543. 
 
ABSTRACT 
In this report we describe our ongoing target repurposing efforts focused on discovery of inhibitors of the essential trypanosomal phosphodiesterase 
TbrPDEB1. This enzyme has been implicated in virulence of Trypanosoma brucei, the causative agent of human African trypanosomiasis (HAT). We 
outline the synthesis and biological evaluation of analogs of tadalafil, a human PDE5 inhibitor currently utilized for treatment of erectile dysfunction, 
and report that these analogs are weak inhibitors of TbrPDEB1. 
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Human African trypanosomiasis (HAT), is a significant neglected tropical disease. Currently, around 50 million people are at risk of 
contracting HAT, and annually the incidence of HAT infections is estimated at 50,000.1,2 The current therapies are severely limited by 
cost, route of administration, toxicity to the patient, and drug resistant trypanosomes.3 The genome of Trypanosoma brucei codes for 
five different PDEs, and two of these (TbrPDEB1 and TbrPDEB2) are closely related and demonstrated to be required for virulence.4,5 
These enzymes have been demonstrated to be viable drug targets for trypanosomiasis.6-8 
As a rapid and cost-effective approach to neglected tropical disease (NTD) drug discovery, we employ a "target repurposing” 
approach.9 This approach entails the identification of potential targets in the parasite that show homology to biological targets in 
humans that have already been pursued for drug discovery efforts. Knowledge from these drug discovery efforts can be repurposed in 
the design, synthesis, and optimization of new agents that inhibit the parasite targets. Furthermore, since the human homolog is likely to 
be a potential off-target in an antiparasitic treatment, previous knowledge about pharmacology of the lead molecule chemotype can be 
readily employed. 
We describe in this article, and in the preceding article,10 a focus on the synthesis and assessment of analogs of established PDE5 
inhibitors. We8 and others7,11 have shown that some human PDE inhibitors and their analogs display various degrees of inhibition 
towards the parasitic enzymes. We observed that tadalafil showed a lack of activity against TbrPDEB1 at 100 µM drug concentrations. 
Nevertheless, owing to the particularly extensive history in human PDE5 inhibitor medicinal chemistry, we were inclined to explore this 
chemotype by designing a variety of analogs based on the tadalafil scaffold. Furthermore, the tadalafil scaffold has been pursued by 
others as antimalarial lead compounds12 and trypanocides.13  
To guide our synthetic efforts we first considered the interactions made by tadalafil with human PDE5 that have been reported by 
others.14 In PDE5, the benzo[1,3]dioxole moiety points into a hydrophobic pocket that, based on homology modeling of the T. brucei 
enzymes, is predicted to be deeper.8 Such a pocket, referred to as the P- (or parasite) pocket, has also been demonstrated by X-ray 
crystallography to exist in the  
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Figure 2. Putative position of tadalafil in the TbrPDEB1 binding site. 
Leishmania major homolog, LmjPDEB1.15 The indole N-H interacts with the glutamine residue that is conserved across all known 
PDEs. The western end of tadalafil points towards a small lipophilic sub-pocket adjacent to the metal binding pocket in the human 
enzyme; our homology model of the parasitic enzyme suggests the presence of some polar amino acids in this region.8   
A handful of analogs that explored these regions were prepared (Scheme 1). Treatment of the appropriate tryptophan methyl ester 
under Pictet-Spengler conditions in the presence of the appropriate aldehydes provided intermediates 1. Then, acylation with 
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chloroacetyl chloride in the presence of triethylamine gave the chloroacetyl derivatives 2 in good yield. The piperazinedione derivatives 
3 were obtained by reaction with methyl amine in refluxing methanol. 
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Scheme 1. Conditions: (a) R2-CHO, CH2Cl2, CF3COOH,  0
 ºC to rt; (b) chloroacetyl chloride, Et3N, CH2Cl2; (c) CH3NH2-HCl, MeOH, Et3N, reflux; (d) NaH, 
MeI, THF. (Refer to Table 1 for R2) 
Preparation of N-methylated analogs of tadalafil and its C6 epimer was achieved by reacting the parent compound with sodium 
hydride and methyl iodide, giving 4a and 4b. The brominated analog 5 was prepared by applying the Scheme 1 reaction sequence, 
starting with 5-bromotryptophan. Compound 5 could be reacted under Suzuki conditions to provide the pyrazole analog 6 (Scheme 2). 
This sidechain was specifically selected among other options for its small size and H-bond donor-acceptor functionality, which may 
interact with the small polar pocket observed to be adjacent to the metal binding site. 
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Scheme 2. Conditions: (a) 1H-pyrazol-5-ylboronic acid, aq. Na2CO3, Pd(dppf)Cl2, dioxane, 90 ºC, overnight. 
 
We also wished to explore the solvent-exposed region by truncation of the diketopiperazine moiety. This was achieved by treatment 
of intermediate 1 with ammonium hydroxide to give the tri-cyclic analogs 7-10 (Scheme 3).  
Additional analogs to explore the P-pocket region were synthesized by the sequence in Scheme 1, using CBZ-glycinal in the Pictet-
Spengler reaction/cyclization sequence to give 3a. Deprotection of 3a (Scheme 4) by catalytic hydrogenation provided the amine 
template 11, that could be acylated (to provide 12 or 13) or alkylated (to provide 14). These analogs 
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Scheme 3. (a) NH4OH, Dioxane, rt.  
 
were designed in order to both probe the steric accessibility of the P- pocket, and to interact with the putative H-bond donors/acceptors 
present. 
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Scheme 4. Conditions: (a) H2, Pd/C, EtOH, 3h; (b)Ac2O, DIEA, THF, 24h, rt; (c) 3-methyl-1H-pyrazole-4-carboxylic acid, EDC, Et3N, HOBt, CH2Cl2; (d) 
nicotinaldehyde, NaBH(OAc)3, THF/DMF, 48 h. 
 
Finally, 15 was prepared in an analogous manner to the analogs shown in Scheme 1, starting from tryptamine (Scheme 5).  
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Scheme 5. Conditions: (a) piperonal, CH2Cl2, CF3COOH,  0 ºC to rt ; (b) acetyl chloride, Et3N, THF, rt.  
All the tadalafil analogs synthesized were screened against TbrPDEB18 and the data is summarized in Tables 1 and 2. The tricyclic 
analogs in Table 1 show weak activity. Although tadalafil showed no inhibition at 100 µM (Table 2) its C6 epimer 16 displayed almost 
40% inhibition at the same concentration. Compound 15, showed very weak activity (17% inhibition). The other compounds in Table 2 
show low-to-modest potency, including those that explored the putative P-pocket. However, compound 6, which was designed to 
interact with a small sub-pocket adjacent to the metal binding region displayed 72% inhibition at 10 µM. Unfortunately, a reliable dose-
response experiment was not possible with this analog due to poor solubility at higher concentrations. 
In conclusion, the goal of these experiments was to broadly explore the structure-activity relationships of the tadalafil scaffold. Most 
analogs synthesized displayed a poor inhibition profile with the notable exception of 6. Given the fairly flat SAR and low potencies 
observed, we confirm that the tadalafil scaffold does not hold as strong promise for potent TbrPDEB1 inhibitors as the PDE4 
chemotypes previously disclosed.8 
Table 1. Potencies of tricyclic tadalafil analogs against TbrPDEB1. 
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aInhibitor concentration 100.0 µM. bInhibitor concentration 10.0 µM. 
Table 2. Tadalafil analogs tested against TbrPDEB1. 
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aInhibitor concentration 10.0 µM. b Inhibitor concentration 100.0 µM. 
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publically available as a public data set in the Collaborative Drug Discovery database (www.collaborativedrug.com).   
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